Floatz logo

Miricorilant

Non-alcoholic Fatty Liver Disease (NAFLD)

Corcept TherapeuticsSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Non-alcoholic Fatty Liver Disease (NAFLD) cohort.

Asset / SponsorPhaseRating
Docosahexaenoic Acid
Hawler Medical University
Phase 3BB
SORBITOL
ScandiBio Therapeutics AB
Phase 2B
SERINE
ScandiBio Therapeutics AB
Phase 2B
lcq908
Novartis Pharmaceuticals
Phase 2B
Nicotinamide Ribonucleoside
ScandiBio Therapeutics AB
Phase 2B

View all 11 →

Same molecule, other indications

Miricorilant is also rated in:

obesity disorderDormant
BB
Indicative ·
69 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
60 / 100
View asset →
Antipsychotic Induced Weight GainDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →